Related Experiment Video
Updated: Jun 22, 2026
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
[Vaspin and insulin resistance].
1Department of Medicine, Okayama University Hospital, Okayama 700-8558.
Rinsho Byori. the Japanese Journal of Clinical Pathology
|September 20, 2008
Summary
Researchers identified the vaspin gene, which is linked to obesity and type 2 diabetes. Vaspin levels change with body weight and diabetes progression, and its administration improves metabolic health, suggesting therapeutic potential.
Area of Science:
- Endocrinology
- Metabolic Syndrome Research
- Molecular Biology
Background:
- Otsuka Long-Evans Tokushima fatty (OLETF) rats, an animal model for abdominal obesity and type 2 diabetes, exhibit altered gene expression in visceral white adipose tissues (WATs).
- Understanding the molecular mechanisms underlying metabolic syndrome is crucial for developing effective therapeutic strategies.
Purpose of the Study:
- To identify novel genes involved in the pathogenesis of metabolic syndrome.
- To investigate the role of the vaspin gene (serpina12) in obesity and type 2 diabetes.
- To explore the therapeutic potential of vaspin and its analogues.
Main Methods:
- Gene expression analysis in OLETF rats at different ages and body weights.
- Administration of thiazolidinediones (pioglitazone) to assess vaspin mRNA levels.
- Administration of recombinant vaspin to high-fat, high-sucrose (HFHS) diet-induced obese mice.
Main Results:
- Vaspin mRNA was significantly upregulated in visceral WATs of OLETF rats, correlating with peak body weight.
- Vaspin mRNA levels decreased with worsening diabetes and body weight loss but increased with pioglitazone treatment.
- Recombinant vaspin administration improved glucose tolerance and insulin sensitivity in obese mice.
Conclusions:
- Vaspin may function as a compensatory molecule in metabolic syndrome.
- Vaspin recombinant protein or vaspin-mimicking agents represent potential therapeutic targets for drug discovery and development in metabolic disorders.
More Related Videos
Related Concept Videos
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.